Wednesday, April 29, 2020

First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed

Treatment with the antiviral drug remdesivir does not speed recovery from COVID-19 compared with placebo in hospitalized patients who are critically ill, according to the first randomized trial of its kind involving 237 adults from 10 hospitals in Wuhan, China.

from Latest Science News -- ScienceDaily https://ift.tt/2yaINPy
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Only 13 % know: The one-minute self-exam that could save young men’s lives

A new survey shows most Americans wrongly think testicular cancer is an older man's issue, despite it most commonly affecting men aged 2...